Congress tradeHeld by the filer's joint per the disclosure. Disclosed 38 days after the transaction; reported as an official range, not an exact amount.
Loading…
Traded Nov 18, 2025 · Filed Nov 20, 2025
Quest Diagnostics's SVP & Chief Commercial Officer sold $1.49M of Quest Diagnostics shares. It was planned long ago, so it says very little.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$1,488,683
Shares × reported transaction price
28 days after results of Oct 21, 2025, 55 days before results of Jan 12, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $185.32 on Nov 18, 2025, within 3% of its 52-week high, after a 2% rise over the previous 30 trading days
52-week range $150.33 (Jan 15, 2025) to $190.58 (Sep 30, 2025), 87% of the way up, from 250 adjusted closes. 30 trading days earlier: $181.89 on Oct 7, 2025. Describes the past only, not a forecast
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | -1.1% | +3.7% | -4.8% |
| 30 days | -7.8% | +3.9% | -11.7% |
| 90 days | +5.8% | +3.9% | +2.0% |
| 180 days | +1.3% | +12.5% | -11.2% |
Past results only. Not a forecast.
Held by the filer's joint per the disclosure. Disclosed 38 days after the transaction; reported as an official range, not an exact amount.
18K → 17K shares held−7% of their stake
A board member of Quest Diagnostics sold $240K of Quest Diagnostics shares. Nobody planned it ahead of time.
Derivative exercise or conversion — not an open-market buy.
